Epax was part of Trygg Pharma Group, an omega-3 pharmaceutical company. This acquisition, which is effective immediately, is hoped will strengthen and expand FMC’s presence in the high growth nutraceutical market.
FMC’s acquisition will include Epax’s two production facilities in Alesund, Norway, and Seal Sands, UK. The transaction, valued at approximately $345m, reflects a 2013 Ebitda multiple in line with FMC’s current trading multiple, and is expected to be immediately accretive to earnings per share.
© FoodBev Media Ltd 2024